Syndax Pharmaceuticals (DB:1T3) - Hisse Senedi Fiyatı, Haberler ve Analizler

1T3 Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Syndax Pharmaceuticals, Inc. kanser tedavisi için terapiler geliştirmektedir. Daha fazla detay

1T3 temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 43.87% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda dalgalı hisse senedi fiyatı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Syndax Pharmaceuticals, Inc. Rakipler

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€848.4m

4SC

DB:VSC

€48.2m

Heidelberg Pharma

XTRA:HPHA

€102.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Syndax Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$15.70
52 Haftanın En Yüksek Seviyesi	US$22.20
52 Haftanın En Düşük Seviyesi	US$13.80
Beta	0.92
11 Aylık Değişim	-8.72%
3 Aylık Değişim	-14.21%
1 Yıllık Değişim	13.77%
33 Yıllık Değişim	8.28%
5 Yıllık Değişim	141.54%
Halka arzdan bu yana değişim	8.52%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	1T3	DE Biotechs	DE Pazar
7D	6.8%	-0.2%	0.8%
1Y	13.8%	-16.9%	9.1%

Getiri vs. Endüstri: 1T3 geçen yıl % -16.9 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: 1T3 geçen yıl % 9.1 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 1T3's price volatile compared to industry and market?
1T3 volatility
1T3 Average Weekly Movement	9.2%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 1T3 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 1T3 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2005	184	Michael Metzger	www.syndax.com

Klinik aşamada bir biyofarmasötik şirketi olan Syndax Pharmaceuticals, Inc. kanser tedavisi için tedaviler geliştirmektedir. Öncü ürün adayları, KMT2A yeniden düzenlenmiş, akut lösemiler ve solid tümör tedavisi için menin-MLL bağlanma etkileşiminin güçlü, seçici, küçük moleküllü bir inhibitörü olan revumenib ve kronik graft versus host hastalığı (cGVHD) ve idiyopatik pulmoner fibrozis (IPF) hastalarının tedavisi için koloni uyarıcı faktör 1 veya CSF-1 reseptörünü bloke eden monoklonal bir antikor olan SNDX-6352 veya aksatilimab'dır. Şirket ayrıca Entinostat'ı da geliştirmektedir.

Syndax Pharmaceuticals, Inc. Temel Bilgiler Özeti

Syndax Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
1T3 temel i̇stati̇sti̇kler
Piyasa değeri	€1.31b
Kazançlar(TTM)	-€283.55m
Gelir(TTM)	€15.27m

85.8x

P/S Oranı

-4.6x

F/K Oranı

1T3 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
1T3 gelir tablosu (TTM)
Gelir	US$16.00m
Gelir Maliyeti	US$64.19m
Brüt Kâr	-US$48.19m
Diğer Giderler	US$248.87m
Kazançlar	-US$297.06m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.48
Brüt Marj	-301.21%
Net Kâr Marjı	-1,856.64%
Borç/Özkaynak Oranı	0%

1T3 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

1T3 Stoklara Genel Bakış

Ödüller

Risk Analizi

Syndax Pharmaceuticals, Inc. Rakipler

XTRA:BIO3

€1.4b

XTRA:FYB

€848.4m

DB:VSC

€48.2m

XTRA:HPHA

€102.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

New minor risk - Share price stability

Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib

Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Recent updates

Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

New minor risk - Share price stability

Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib

Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

New minor risk - Share price stability

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

New minor risk - Profitability

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Now 24% undervalued

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

New minor risk - Share price stability

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

First half 2022 earnings released

Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer

Investor sentiment improved over the past week

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.54 loss in 1Q 2021)

Syndax Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Syndax Pharmaceuticals, Inc. Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.46 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.